{
    "organizations": [],
    "uuid": "f755a659c643c0a6e2d614b9f44fc9884199a764",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-redhill-biopharma-posts-q1-loss-of/brief-redhill-biopharma-posts-q1-loss-of-0-05-per-ordinary-share-idUSASC0A0EV",
    "ord_in_thread": 0,
    "title": "BRIEF-Redhill Biopharma Posts Q1 Loss Of $0.05 Per Ordinary Share",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "May 8 (Reuters) - Redhill Biopharma Ltd:\n* REDHILL BIOPHARMA REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS\n* Q1 REVENUE $2.4 MILLION * REDHILL BIOPHARMA - DOES NOT HAVE PLANS TO RAISE ADDITIONAL CAPITAL AHEAD OF MAP US PHASE III STUDY TOP-LINE RESULTS WITH RHB-104 FOR CROHNâ€™S DISEASE\n* QTRLY LOSS PER ORDINARY SHARE $0.05 * CASH BALANCE AS OF MARCH 31, 2018 WAS $36.4 MILLION, COMPARED TO $46.2 MILLION AS OF DECEMBER 31, 2017 Source text for Eikon: Further company coverage: (Reuters.Briefs@thomsonreuters.com)\n ",
    "published": "2018-05-08T19:30:00.000+03:00",
    "crawled": "2018-05-09T12:28:42.009+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "may",
        "reuters",
        "redhill",
        "biopharma",
        "ltd",
        "redhill",
        "biopharma",
        "report",
        "first",
        "quarter",
        "financial",
        "result",
        "q1",
        "revenue",
        "million",
        "redhill",
        "biopharma",
        "plan",
        "raise",
        "additional",
        "capital",
        "ahead",
        "map",
        "u",
        "phase",
        "iii",
        "study",
        "result",
        "crohn",
        "disease",
        "qtrly",
        "loss",
        "per",
        "ordinary",
        "share",
        "cash",
        "balance",
        "march",
        "million",
        "compared",
        "million",
        "december",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}